News

NITI Aayog readying Make In India fillip for domestic medical devices

Maitri Porecha New Delhi | Updated on January 07, 2020 Published on January 07, 2020

A preliminary list of 10 device-categories with most export potential have been drawn up for prioritising domestic production. More can be added later, said officials   -  Volodymyr Kryshtal

‘Too many departments are involved in approvals. We want to hasten the process’

To eliminate bottlenecks in domestic medical devices businesses, government think-tank NITI Aayog is drawing up a list of devices which have most potential for export. A tentative list of 10 such device-categories has been drawn up, officials said.

Preliminary list

Devices under the NITI Aayog scanner for providing priority subsidy or funding are cardiac stents, orthopaedic implants, surgical blades, catheters, X-Ray machines, syringes and needles, blood bags, CT Scan and MRI Machines as well as sutures. “This list is being drawn up so that their domestic manufacturing can be prioritised. However, more devices are slated to be added in follow-up meetings. This is a preliminary list,” an official, who was present at a meeting called by NITI Aayog told Businessline.

The meeting was chaired by VK Saraswat, Member, Science and Technology, NITI Aayog, who said that the government was looking at a single window framework for accelerating standardisation, body certification, declaring the device safe and so on. “Currently there are too many departments involved in giving approvals, and thus they get delayed. We want to hasten this process,” Saraswat said.

Export boost

Sources said that the government is contemplating reimbursement to the company if the registration registration takes place in foreign countries. “Reimbursement of costs incurred while conducting clinical trials, as well as that for conducting Research and Development, patent filing charges will also be looked into,” said the source. A domestic stent manufacturer who did not want to be quoted said, “In the last clinical trial we undertook for getting registered our stent product with the USFDA, we spent close to ₹200 crore. This when we are already licensed by Indian regulators and our product is certified. There are a number of bottlenecks for domestic companies to boost exports. The government is looking at incentives like subsidies and preference, so that the exports of Indian products receives a fillip.”

Himanshu Baid, Chairman, CII Medical Technology Division said that all countries provide incentives to their domestic manufacturers for boosting their business.

“Our biggest competitor is China, and largely their industry is thriving on domestic production (up to 95 per cent), India needs to give it’s domestic industry,” he said.

Published on January 07, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
NITI Aayog
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.